dokumendiregister.ee
Sissetulev kiriAvalik

Euroopa farmakopöa töökava asjus

Ravimiamet · 25. september 2024
Viit
REP-1/3446-1
Registreeritud
25. september 2024
Dokumendi liik
Sissetulev kiri
Adressaat
European Directorate for the Quality of Medicines & HealthCare
Saabumis/saatmisviis
e-post
Funktsioon
REP Euroopa Farmakopöaga seotud asjaajamine
Sari
REP-1 Euroopa Farmakopöa alane kirjavahetus
Toimik
REP-1/2024
Vastutaja
Signe Leito (RA, Labor)

Failid

Sisu (failidest)

Signe Leito Saatja: [email protected] Saatmisaeg: esmaspäev, 23. september 2024 16:51 Adressaat: Signe Leito Teema: Survey for information on approved products containing anhydrous ephedrine, ephedrine hemihydrate or ephedrine hydrochloride, racemic Gp10A: EDQM-2024-03790-mail Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Please make sure to include in any reply our mail reference: EDQM-2024-03790-mail **************************************************************************** European Pharmacopoeia Commission Secretariat RZ/PH/ 2024-03760L Strasbourg, 23 September 2024 JSB/mk LETTER FOR THE ATTENTION OF NPAs Copy: Presidium Dear Colleagues, Please find below the link to an enquiry being carried out on information regarding "the ephedrines": https://survey.edqm.eu/index.php?r=survey/index&sid=551518&lang=en In order to have access to the enquiry, please copy and paste the link into your Internet browser. Deadline for replies: 4 November 2024. Best regards, On behalf of Dr Jaume Sanz-Biset Mireille Kopf 1 Secretarial Assistant European Pharmacopoeia Department EDQM - Council of Europe Tel.: +33 (0)3 88 41 28 53 / Fax: +33 (0)3 88 41 27 71 https://www.edqm.eu / https://store.edqm.eu Stay connected with the EDQM Confidentiality Notice: This e-mail and any attached files may contain confidential information that is intended only for the addressee(s). If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail (including any attached files) is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by using the reply function and then permanently delete this e-mail (including any attached files). Thank you. ************************************************************************** Please make sure to include in any reply our mail reference: EDQM-2024-03790-mail 2
Allikas: Ravimiamet dokumendiregister →